1401031-37-5

Usage

Class

Acetonitriles
It belongs to a class of organic compounds that have a cyano group (C≡N) attached to an alkyl or aryl group.

Pyridine ring

The compound contains a pyridine ring, which is a six-membered aromatic ring with one nitrogen atom replacing one carbon atom in a benzene ring.

Spiro decane ring structure

It features a spiro decane ring, which is a non-aromatic six-membered carbon ring connected to another six-membered carbon ring through a shared carbon atom.

Complexity

The compound is considered complex due to the presence of both a pyridine ring and a spiro decane ring structure, making it a unique chemical.

Potential applications

The compound has potential applications in various fields such as pharmaceuticals, agrochemicals, and material science.

Further research needed

More research and studies are necessary to determine the specific properties and potential uses of 2-[(9S)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]acetonitrile in various industrial and scientific applications.

Upstream product

• 855398-58-2 (+/-)-6-oxaspiro[4.5]decan-9-ol 
• 120-92-3 cyclopentanone 
• 855398-57-1 6-oxa-spiro[4.5]decan-9-one 

Downstream Products

• 1401031-38-6 2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]acetonitrile 
• 1401028-24-7 TRV-130 
• 1401031-28-4 2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]acetaldehyde 

Relevant academic research and scientific papers

mu-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE

Disclosed are a class of μ-opioid receptor agonists and a preparation method therefor and the use thereof in the field of medicine, belonging to the field of medicinal chemistry. The μ-opioid receptor agonists significantly increase the selectivity for a G protein signaling pathway, and not only can exhibit excellent pharmacodynamic effects, but also significantly improve safety.

Opioid receptor agonists and application thereof

The invention discloses compounds and salts thereof that can be used as opioid receptor ligands, a preparation method of the compounds, compositions containing the compounds, and a use of the compounds as [mu] opioid receptor agonists; the compounds are used for treatment of [mu] opioid receptor-mediated related diseases, such as pains and pain-related disorders.

DEUTERATED COMPOUNDS FOR TREATING PAIN

The invention provides novel chemical compounds useful for treating pain or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

DEUTERATED COMPOUNDS FOR TREATING PAIN

The invention provides novel chemical compounds useful for treating pain or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

COMBINATIONS OF OPIOID RECEPTOR LIGANDS AND CYTOCHROME P450 INHIBITORS

This application described compounds that can act as opioid receptor ligands, and compositions comprising the compounds and cytochrome P450 inhibitors, which can be used in the treatment of, for example, pain and pain related disorders.

Structure-activity relationships and discovery of a g protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9 r)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain

The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another. There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs. The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events. Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 ((R)-30). This novel molecule demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clinical development. It is currently being evaluated in human clinical trials for the treatment of acute severe pain.